论文信息 - Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer - 字舞流文

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

K. Jensen | A. Gutin | V. Abkevich | S. Bose | W. Audeh | R. Wenstrup | A. Hartman | K. Timms | M. Telli | C. Neff | Z. Sangale | J. Hellyer | S. Vinayak | Elisha Hughes | J. Ford | Joshua T. Jones | Pei-Jen Chang | R. N. Peterson | Zaina Sangale